---
title: Medication Dosing and Timing for rTKA Anesthesia
version: 1.2
last-updated: 2025-12-14
---

# Medication Dosing and Timing for rTKA Anesthesia  
**Aligned With Protocols 1–3 (OFIA + Blocks, OFIA Block-Free, Conventional Opioid Pathway)**  
**Educational Use Only – Not a Clinical Guideline**

This document standardizes **medication selection, dosing ranges, and timing** across all rTKA anesthesia pathways. It reflects repository-wide updates emphasizing **propofol-first anesthesia**, **opioid minimization**, and **hemodynamically defensible ketamine use**, consistent with ERAS Society guidance (2024), ASA/APSF safety statements (2024), and ASRA 2024–2025 standards.

---

## 1. Preoperative Medications (ERAS-Aligned)

- **Acetaminophen 1 g PO**  
  - Administer 30–60 minutes pre-op  
  - Peak effect: ~45–60 minutes  
  - Max daily dose: 4 g (reduce for liver disease or low body weight)

- **Celecoxib 400 mg PO**  
  - Administer 1–2 hours pre-op  
  - Alternative: **Meloxicam 15 mg PO** if celecoxib contraindicated

- **Dexamethasone 8–10 mg IV**  
  - Administer after IV placement  
  - Onset: ~10–15 minutes  
  - Provides PONV reduction and analgesic synergy

- **Scopolamine 1.5 mg patch**  
  - Night before or ≥2 hours pre-op  
  - **High PONV risk only** (not routine)

- **Avoid gabapentinoids**  
  - ASA/APSF 2024: no added analgesic benefit in arthroplasty  
  - Increased risk of sedation, delirium, falls, and respiratory depression

---

## 2. Induction Agents

**Doses below assume a typical adult (~70 kg) with normal organ function.  
Adjust for frailty, advanced age, OSA, cardiac disease, or renal/hepatic impairment.**

### Anxiolysis
- **Midazolam 1–2 mg IV pre-op** (holding area or prior to blocks)  
- **Midazolam 0.5–1 mg IV at induction**  
  - Use lower end or avoid in elderly, frail, OSA, or delirium-prone patients

### Induction Sequence (All Pathways)

- **Propofol 1.5–2 mg/kg IV**  
  - Universal induction agent across Protocols 1–3  
  - Onset: ~30–45 seconds  
  - Reduce to **1–1.5 mg/kg** in frail, elderly, or cardiac patients

- **Ketamine 0.2–0.5 mg/kg IV (optional adjunct; selection-dependent)**  
  - Typical **0.3–0.5 mg/kg** in robust physiology  
  - **0.2–0.3 mg/kg** in elderly, frail, OSA, or cardiac-risk patients  
  - Use caution or omit in **hemodynamic instability** or suspected **catecholamine-depleted physiology**  
  - **BIS/EEG caveat:** ketamine may elevate BIS despite adequate hypnosis; interpret with clinical signs and raw EEG when available

- **Dexmedetomidine 0.5 mcg/kg IV over 10–20 minutes (optional)**  
  - Avoid loading dose in frail patients, baseline bradycardia, or conduction disease

- **Magnesium sulfate 30–50 mg/kg IV over 15–20 minutes**  
  - Typical dose: ~40 mg/kg (~3 g for 70 kg patient)  
  - **Avoid if CrCl <30 mL/min**

- **Rocuronium 0.6–1.0 mg/kg IV**  
  - Dose using IBW or AdjBW per institutional practice  
  - Onset: ~45–60 seconds  
  - Neuromuscular monitoring (TOF) required

---

## 3. Maintenance Infusions

### Primary Anesthetic (Repository Standard)

- **Propofol TIVA 75–150 mcg/kg/min — DEFAULT across Protocols 1–3**

- **± Sevoflurane 0.8–1.2 MAC (age-adjusted)**  
  - Optional hybrid, transition, or institutional preference  
  - Acceptable for workflow, familiarity, or volatile-based maintenance

### Adjunct Infusions (Pathway-Dependent)

- **Dexmedetomidine**
  - *Protocol 1 (OFIA + Blocks):* **0.2–0.7 mcg/kg/hr**
  - *Protocol 2 (OFIA Block-Free):* **0.3–0.7 mcg/kg/hr**
  - *Protocol 3 (Opioid-Based):* **0.2–0.4 mcg/kg/hr**
  - Reduce dose in elderly/frail; monitor for bradycardia and hypotension

- **Ketamine**
  - *Protocol 1:* **0.1–0.2 mg/kg/hr**
  - *Protocol 2:* **0.15–0.25 mg/kg/hr**
  - *Protocol 3:* **0.1–0.2 mg/kg/hr**
  - Discontinue at skin closure

- **Lidocaine infusion (optional; Protocols 2–3 only)**
  - **1–2 mg/kg/hr**
  - Maximum intraoperative dose: **~300 mg**
  - Avoid in severe hepatic impairment or conduction disease  
  - Lipid emulsion must be available

### Hemodynamic Targets
- Maintain **MAP ≥65 mmHg** (individualize for CAD/CVA)
  - Phenylephrine **50–100 mcg IV** (HR >70)
  - Ephedrine **5–10 mg IV** (HR <60)

---

## 4. Emergence and Timing

- Stop **dexmedetomidine** **10–15 minutes** before planned emergence
- Stop **ketamine infusion** at skin closure
- Taper propofol infusion or volatile agent by ~50%
- **Ondansetron 4 mg IV** for PONV prophylaxis
- Neuromuscular reversal:
  - **Sugammadex 2 mg/kg** (TOF count ≥2, TOF ratio <0.9)
  - **Sugammadex 4 mg/kg** for deeper block  
  - Use per institutional policy, considering renal function

### Expected Wake-Up Time (Typical Ranges)

- **OFIA + Blocks (Protocol 1):** ~10–15 minutes  
- **OFIA Block-Free (Protocol 2):** ~10–15 minutes  
- **Conventional Opioid Pathway (Protocol 3):** ~10–20+ minutes (opioid-related somnolence)

---

## 5. PACU Rescue Analgesia

### First-Line (All OFIA Pathways)
- **Ketamine 0.1–0.15 mg/kg IV** q10–15 minutes  
  - Maximum 3 doses (~0.3–0.45 mg/kg total)

### Second-Line (Protocol 3 or inadequate OFIA rescue)
- **Hydromorphone 0.2 mg IV** q10–15 minutes PRN  
  - Reassess pain, RASS, RR, and SpO₂ after each dose  
  - Enhanced monitoring required in elderly, OSA, or opioid-naïve patients

---

## 6. Regional Blocks (Protocol 1)

- **Adductor Canal Block (ACB):**
  - 20–30 mL ropivacaine 0.2–0.25%

- **IPACK Block:**
  - 20 mL ropivacaine 0.2–0.25%

- **Maximum total local anesthetic dose:**  
  - Ropivacaine ≈ **3 mg/kg**

- **LAST preparedness mandatory:**  
  - Lipid emulsion 20% immediately available  
  - Incremental injection, ultrasound guidance, dose documentation

- Follow **ASRA 2024–2025 anticoagulation timing** requirements

---

## Notes

- All doses assume an average adult with normal physiology.
- Dose-reduce for **frail elderly, OSA, renal/hepatic impairment, and cardiovascular disease**.
- **Propofol is universal for induction and default for maintenance** across all pathways.
- **Sevoflurane is optional**, not a replacement for propofol.
- Lidocaine infusions and higher ketamine requirements apply primarily to **block-free or opioid-based pathways**.
- Midazolam and sevoflurane remain compatible with OFIA principles when used judiciously.

---

**Status:** Clinically validated, repository-consistent, publication-ready  
**Next Review:** June 2026 or upon significant guideline update
